Methods for preparing T-cells for cell therapy
T-cells are generated with enhanced immunostimulatory capabilities for use in self therapy treatment protocols, by utilizing a biodegradable device with a biodegradable support that has one or more agents that are reactive to T-cell surface moieties. The biodegradable devices are mixed with the T-cells sufficiently so that the one or more agents cross-link with the T-cells' surface moieties and deliver a signal to the T-cells to enhance immunostimulatory capabilities.
1. A method for generating T-cells for use in cell therapy comprising:
labeling T-cells with a first array of second materials specific for T-cell surface antigens;
applying a universal cross-linking agent comprising a support coated with a first material to said labeled T-cells;
adding another array of second materials specific for T-cell surface antigens to the labeled T-cells; and
applying additional universal cross-linking agent to said labeled T-cells.
2. The method of claim 1 wherein the steps of adding another array of second materials and applying additional universal cross-linking agent are repeated.
3. The method of claim 2 wherein each successive array of second materials has at least one second material that is different from the preceeding array of second materials.
4. The method of claim 1 wherein the arrays of second materials comprise antibodies.
5. The method of claim 1 wherein the arrays of second materials include one or more of the following: anti-CD3, -CD28, -B7-H3, -PD-L1, -PD-L2, -IL-15R, -CD2, -CD48, -LFA-1, -CD43, -CD45, -CD4, -CD8, -CD7, -GM1, -LIGHT, -CD27, -OX40, -4-1BB, -CD30,-CD44, -CD31, -CD18/CD11a, -CD29, -CD54, -CD62L, -VLA4, -IL-2R, -IL-4R, IL-10R, -type II IFNR1 and R2, -type I IFNR, -IL-12beta1 and beta2, -IL-15R, -TNRF1, -TNFR2, and -IL-1R.
6. The method of claim 1 wherein the arrays of second materials include anti-chemokine receptors.
7. The method of claim 6 wherein the anti-chemokine receptors include C-C and C-X-C categories of anti-chemokine receptors.
8. The method of claim 7 wherein the anti-chemokine receptors include one or more of the following: CCR1, CCR2, CCR3, CCR4, CCR5 and CXCR3.
9. The method of claim 1 wherein the support is a biodegradable support.
10. The method of claim 1 wherein the T-cells produced are used in cell therapy to stimulate immunity.
11. The method of claim 1 wherein the T-cells produced are used to suppress immunity.